What we’re looking for

The Psychiatry Consortium is seeking project proposals which focus on the validation of novel molecular drug-targets for mental health conditions, in particular:

  • psychotic disorders
  • affective disorders
  • cognitive disorders
  • psychiatric symptoms associated with dementia

The Psychiatry Consortium intend to fund projects which:

  • are supported by robust evidence that links the molecular target to human disease, which can be further developed or validated,
  • provide a sound therapeutic hypothesis of how target modulation may have a therapeutic effect,
  • will enable tools for target validation e.g. through optimisation of existing tool compounds to improve selectivity, potency, bioavailability

Projects seeking to identify target modulation biomarkers relevant to disease will also be in scope.

A key priority for us whilst reviewing applications is whether proposals are supported by robust evidence linking the molecular target to human disease and of target modulation having a therapeutic effect. The Psychiatry Consortium is perfectly positioned to support researches further develop or validate this initial package of evidence.

Applications which are supported by robust evidence that links the target to the human condition, and provide a sound therapeutic hypothesis of how target modulation may have a therapeutic effect stand the best chance of success.

Our funding is open to universities, research institutes and small companies (micro and medium) worldwide.

Projects are expected to last up to 2 years, with total project costs between £150,000 – £600,000.

We are now accepting applications

Deadline: 1pm (BST) 8th October 2021


What we will NOT fund:

  • projects focused on well-studied targets and pathways for psychiatry diseases
  • projects with advanced chemistry e.g. lead/candidate molecules already synthesised and requiring only in vivo PK studies, preclinical proof-of-concept studies or IND-enabling studies
  • non-pharmacological interventions
  • purely academic explorations of new animal or cellular models (unless there is a clear drug discovery application, e.g. using the model as a tool for validating a new target)
  • early target identification studies without a proposed target (i.e. projects that are mostly characterization and/or hypothesis generating studies)
  • repurposing of existing drugs (unless as a method for validating new molecular targets)
  • clinical trials or clinical studies requiring prospective collection of human samples

What we will offer:

The research projects we support are collaborative in nature, with involvement from the Psychiatry Consortium members in devising the final project plan.

The Psychiatry Consortium will provide the successful applicants access to:

  • drug-discovery expertise
  • drug-discovery capabilities, through specialised Partner Organisations
  • commercial know-how
  • project management resources
  • project funding

Find out more

On 24th September 2021, the Psychiatry Consortium will launch its 4th call for proposals. This time, the application and review process has been reimagined to provide more opportunities for applicants to engage with our funding partners, and to receive additional feedback on their applications.

Psychiatry Consortium Programme Manager, Dr Laura Ajram, outlines the new process in further detail in this short webinar:

View webinar